Results 211 to 220 of about 489,677 (387)
CTHRC1 promotes bone metastasis in prostate cancer
International Journal of Cancer, EarlyView.What's New? The mechanisms driving bone metastasis in prostate cancer are still unclear, and predicting markers have not yet been identified. Based on the biological characterization of prostate cancer cell lines and integrated data analysis of clinical samples, the authors identified CTHRC1 as a candidate gene regulating prostate cancer bone ...
Yuichiro Sawada +18 more
wiley +1 more source
Current status of pediatric urology in India and future directives. [PDF]
Indian J UrolYadav P, Ansari MS, Gundeti MS.
europepmc +1 more source
International Journal of Cancer, EarlyView.What's New? Androgen receptor (AR) alterations contribute to treatment resistance against androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer. This real‐world study demonstrates that AR monitoring via liquid biopsy predicts treatment response and progression in metastatic castration‐resistant prostate cancer.
Regina Stitz +7 more
wiley +1 more source
Risk factors for low‐risk prostate cancer: A retrospective cohort study within the FinRSPC trial
International Journal of Cancer, EarlyView.What's New? Overdiagnosis of low‐risk prostate cancer remains an important downside of prostate‐specific antigen‐based screening. This retrospective cohort study of 80,144 men with a median follow‐up of 18.0 years shows that risk factors for low‐risk prostate cancer differ significantly from those for high‐risk prostate cancer.
Uzoamaka E. Okwor +6 more
wiley +1 more source
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. [PDF]
Nat MedShore ND +20 more
europepmc +1 more source